Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome-Reference-Cited by-同舟云学术

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome

Published:2016-01-13 Issue:1 Volume:69 Page:25-34
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Beckers Rhiannon K¹,Selinger Christina I¹,Vilain Ricardo¹²³,Madore Jason³,Wilmott James S²³,Harvey Kate¹⁴,Holliday Anne⁴,Cooper Caroline L¹²,Robbins Elizabeth¹,Gillett David²⁵,Kennedy Catherine W²⁵,Gluch Laurence²⁵⁶,Carmalt Hugh²⁵⁷,Mak Cindy⁷,Warrier Sanjay²⁷⁸,Gee Harriet E⁹¹⁰,Chan Charles²¹¹,McLean Anna²,Walker Emily²,McNeil Catriona M²¹²,Beith Jane M²¹²,Swarbrick Alexander⁴¹³,Scolyer Richard A¹²³,O'Toole Sandra A¹²⁴¹³

Affiliation:

1. Department of Tissue Pathology and Diagnostic Oncology; Royal Prince Alfred Hospital; Camperdown NSW Australia

2. Sydney Medical School; University of Sydney; Sydney NSW Australia

3. Melanoma Institute Australia; Sydney NSW Australia

4. The Kinghorn Cancer Centre and Cancer Research Program; Garvan Institute of Medical Research; Darlinghurst NSW Australia

5. The Strathfield Breast Centre; Strathfield NSW Australia

6. Department of Breast and Endocrine Surgery; Concord Repatriation General Hospital; Sydney NSW Australia

7. Department of Breast Surgery; Royal Prince Alfred Hospital; Camperdown NSW Australia

8. Department of Surgery; Prince of Wales Hospital; Randwick NSW Australia

9. Department of Radiation Oncology; Sydney Cancer Centre; Royal Prince Alfred Hospital; Camperdown NSW Australia

10. Department of Oncology; Weatherall Institute of Molecular Medicine; John Radcliffe Hospital; University of Oxford; Oxford UK

11. Anatomical Pathology Department; Concord Repatriation General Hospital; Concord NSW Australia

12. Department of Medical Oncology; Chris O'Brien Lifehouse; Camperdown NSW Australia

13. St Vincent's Clinical School; Faculty of Medicine; University of New South Wales; Darlinghurst NSW Australia

Funder

CINSW

Sydney Breast Cancer Foundation

National Health and Medical Research Council

Australian National Health and Medical Research Council

Cancer Institute New South Wales

Melanoma Institute Australia

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.12904/fullpdf

Reference33 articles.

1. Triple-negative breast cancer: role of specific chemotherapy agents;Isakoff;Cancer J.,2010

2. Tissue expression of PD-L1 mediates peripheral T cell tolerance;Keir;J. Exp. Med.,2006

3. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity;Topalian;Curr. Opin. Immunol.,2012

4. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy;Blank;Cancer Immunol. Immunother.,2005

Cited by 190 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer;Journal of Nanobiotechnology;2024-08-01

3. Establishment of an ovarian cancer exhausted CD8+T cells-related genes model by integrated analysis of scRNA-seq and bulk RNA-seq;European Journal of Medical Research;2024-07-05

4. Expression of programmed death ligand 1 in patients with triple‑negative breast cancer: Association with clinicopathological parameters;World Academy of Sciences Journal;2024-06-25

5. Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort;2024-06-13